• Catherine R Sears, Tobias Peikert, Jennifer D Possick, Jarushka Naidoo, Mizuki Nishino, Sandip P Patel, Philippe Camus, Mina Gaga, Edward B Garon, Michael K Gould, Andrew H Limper, Philippe R Montgrain, William D Travis, and M Patricia Rivera.
• Am. J. Respir. Crit. Care Med. 2019 Sep 15; 200 (6): e31e43e31-e43.

AbstractRationale: Immune checkpoint inhibitors (ICIs) have revolutionized cancer care but are associated with unique adverse events, including potentially life-threatening pneumonitis. The diagnosis of ICI-pneumonitis is increasing; however, the biological mechanisms, clinical and radiologic features, and the diagnosis and management have not been well defined.Objectives: To summarize evidence, identify knowledge and research gaps, and prioritize topics and propose methods for future research on ICI-pneumonitis.Methods: A multidisciplinary group of international clinical researchers reviewed available data on ICI-pneumonitis to develop and refine research questions pertaining to ICI-pneumonitis.Results: This statement identifies gaps in knowledge and develops potential research questions to further expand knowledge regarding risk, biologic mechanisms, clinical and radiologic presentation, and management of ICI-pneumonitis.Conclusions: Gaps in knowledge of the basic biological mechanisms of ICI-pneumonitis, coupled with a precipitous increase in the use of ICIs alone or combined with other therapies, highlight the importance in triaging research priorities for ICI-pneumonitis.

27 keywords...

hide…